BHVNのチャート
BHVNの企業情報
| symbol | BHVN |
|---|---|
| 会社名 | Biohaven Pharmaceutical Holding Co Ltd （BIOHAVN PHRMCTCL） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | バイオヘイヴン・ファーマスーティカル・ホールディング(Biohaven Pharmaceutical Holding Company Ltd.)は米国のバイオ医薬品会社である。同社はオーファン神経学的徴候と他の神経学的経路を標的とする臨床段階化合物の同定・開発に従事する。同社は複数の後期薬剤候補のポートフォリオを有する。同社のパイプラインはグルタミン酸調節剤の処方物であるBHV-0223、グルタミン酸を調節するニューケミカルエンティティ（NCE）であるBHV-4157、N-メチル-D-アスパラギン酸（NMDA）受容体拮抗作用を標的とする同社の治験代理人であるBHV-5000を含む。臨床化合物であるトリグリルゾールは神経変性疾患と癌の適応症等に適応される。同社のパイプラインにはBHV-3000とBHV-3500を含む。同社はオーファン・神経科学の適応症における他のメカニズム論的アプローチを進めることに焦点を当て、追加の化合物ライセンスを探査する。 バイオヘイブン・ファ―マシュ―ティカル・ホ―ルディングはイギリス領ヴァ―ジン諸島籍の医薬品メ―カ―持株会社。子会社を通じて、希少疾病を含む神経系疾患の治療薬の開発に従事する。主な候補薬には、片頭痛の急性治療薬「Rimegepant」や脊髄小脳失調症の治療を対象とする「Trigriluzole」がある。本社はコネチカット州ニュ―ヘイブン。 Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. |
| 本社所在地 | c/o Biohaven Pharmaceuticals Inc. 215 Church Street New Haven CT 06510 USA |
| 代表者氏名 | Declan Doogan |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 203-404-0410 |
| 設立年月日 | 41518 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 63人 |
| url | www.biohavenpharma.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） -224.53700 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 2221.54300 |
| 売上高 | （百万ドル） 0.00000 |
| 企業価値(EV) | （百万ドル） 1957.29400 |
| 当期純利益 | （百万ドル） -240.92200 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Biohaven Pharmaceutical Holding Co Ltd revenues was not reported. Net loss applicable to common stockholders increased 73% to $240.9M. Higher net loss reflects Research and development - Balancing val increase from $82.5M to $181.6M (expense) General and administrative - Balancing v increase from $11.8M to $26M (expense) Stock-based Compensation in SGA increase of 36% to $8.6M (expense). |
BHVNのテクニカル分析
BHVNのニュース
Biohaven Non-GAAP EPS of -$1.27 beats by $0.01 2023/03/23 20:39:31 Seeking Alpha
Biohaven press release (BHVN): Q4 Non-GAAP EPS of -$1.27 beats by $0.01.Cash, cash equivalents and marketable securities as of December 31, 2022 was $465.3 million, excluding…
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments 2023/03/23 20:05:00 PR Newswire
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China) rights; Phase 1 clinical trial initiation anticipated in 2023 Completed Phase 1 SAD/MAD study with BHV-7000 from our Kv7 ion channel…
Biohaven acquires rights to potential brain disorder drug BHV-8000 for $10M upfront 2023/03/22 12:20:08 Seeking Alpha
Biohaven (BHVN) said it acquired global rights, excluding China regions, for BHV-8000 to treat brain disorders from Hangzhou Highlightll Pharmaceutical.Highlightll will get…
Biohaven Pharma Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders 2023/03/22 11:43:04 Investing.com
https://www.investing.com/news/pro/biohaven-pharma-acquires-exclusive-license-for-oral-brainpenetrant-dual-tyk2jak1-inhibitor-for-immunemediated-brain-disorders-432SI-3036600
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders 2023/03/22 11:30:00 PR Newswire
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitors Exclusive license covers global rights excluding China…
A stock that deserves closer examination: Biohaven Ltd. (BHVN) 2023/02/07 12:40:00 US Post News
A share of Biohaven Ltd. (NYSE:BHVN) closed at $18.08 per share on Monday, down from $18.19 day before. While Biohaven Ltd. has underperformed by -0.60%, investors are advised to look at stock chart patterns for technical insight. On January 24, 2023, SVB Securities started tracking Biohaven Ltd. (NYSE: BHVN) recommending Outperform. A report published by […]
Here''s What''s Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric 2023/02/02 17:52:41 Investor''s Business Daily
Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.
Pfizer sees steep 2023 fall in COVID-19 vaccine sales, aims to bolster pipeline 2023/02/01 02:55:07 Rappler
Pfizer on Tuesday, January 31, forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment for 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories. Chief executive Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024. Pfizer’s total annual sales crossed the $100-billion mark for the first time in 2022, driven by the more than $56 billion in sales of its COVID-19 vaccine and Paxlovid antiviral treatment. It expects total 2023 revenue of $67 billion to $71 billion. “We are building on a significant capital position that we know how to deploy to create growth,” Bourla told analysts and investors on conference call. “We are building an R&D engine that is more productive than ever.” The company launched five new products last year and hopes to introduce as many as 14 more over the next year and a half, including a vaccine for respiratory syncytial virus (RSV) and an mRNA flu vaccine.
RICE HALL JAMES & ASSOCIATES, LLC Buys 3, Sells 2 in 4th Quarter 2023/01/27 18:00:03 GuruFocus
Related Stocks: AERI , BHVN , DOCS , OABI , RXO ,
Ursa Fund Management, LLC Buys 2, Sells 3 in 4th Quarter 2023/01/27 00:00:18 GuruFocus
Related Stocks: CHNG , ACI , CLM , STAR , BHVN ,
Pfizer boosts COVID vaccine sales forecast by $2 billion 2022/11/01 16:15:29 Kalkine Media
By Manas Mishra (Reuters) -Pfizer Inc on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker''s shares rose 2.4% to $447.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Novavax Inc rose 11%, while Moderna Inc gained about 4%. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. In response, Pfizer plans to roughly quadruple the price of the vaccine, which it sells with German partner BioNTech, in the United States once the government stops buying doses and shifts to a private market. "Our COVID-19 franchises will remain multi-billion-dollar revenue generators for the foreseeable future," Chief Executive Officer Albert Bourla said in prepared remarks ahead of a conference call.
Biohaven Pharma CEO Buys Another $400K in Stock 2022/11/01 12:31:02 Investing.com
https://www.investing.com/news/pro/biohaven-pharma-ceo-buys-another-400k-in-stock-432SI-2928059
Investing in Biohaven Ltd. (BHVN) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/10/31 14:24:00 US Post News
Biohaven Ltd. (NYSE:BHVN) closed Friday at $15.33 per share, up from $13.83 a day earlier. While Biohaven Ltd. has overperformed by 10.85%, investors are advised to look at stock chart patterns for technical insight. On October 26, 2022, Cantor Fitzgerald Upgraded Biohaven Ltd. (NYSE: BHVN) to Overweight. A report published by Piper Sandler on October […]
Biohaven Insider Trades Send a Signal 2022/10/27 14:53:10 Benzinga
Matthew Buten , Chief Financial Officer at Biohaven (NYSE: BHVN ), reported a large insider buy on October 26, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Buten purchased 142,857 shares of Biohaven. The total transaction amounted to $1,499,998. Biohaven shares are trading up 1.25% at $13.78 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com
Biohaven Chief Executive Officer Makes $8.96M Stock Purchase 2022/10/27 14:52:50 Benzinga
Vlad Coric , Chief Executive Officer at Biohaven (NYSE: BHVN ), reported a large insider buy on October 26, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Coric purchased 853,380 shares of Biohaven. The total transaction amounted to $8,960,490. Biohaven shares are trading up 1.25% at $13.78 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com